|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||30.42 - 30.69|
|52 Week Range||28.48 - 36.82|
|PE Ratio (TTM)||20.91|
|Forward Dividend & Yield||1.03 (3.37%)|
|1y Target Est||N/A|
BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.
What Could Drive Bristol-Myers Squibb in 2018? In December 2017, the U.S. FDA (Food and Drug Administration) approved Bristol-Myers Squibb’s (BMY) Opdivo as adjuvant therapy for individuals with melanoma with the involvement of lymph nodes or metastatic disease who have undergone complete resection. The objective of the adjuvant therapy is to reduce the risk of recurrence after surgical removal of the tumor.
Smoking, which causes many lung cancer cases, has made advanced lung cancer a big market for pharmaceutical companies, and the competition has been fierce.
Merck surged to a three-month high Tuesday on strong results for its immuno-oncology and chemotherapy regimen in lung cancer.
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Prothena's (PRTA) stock tumbles more than 18% due to a pipeline setback. The company depends heavily on the success of its two candidates.
Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.
In 3Q17, AbbVie (ABBV) reported global sales of nearly $276 million for its hepatitis C (or HCV) portfolio, which reflected a 27.7% operational fall and a 26.8% reported fall year-over-year (or YoY). The company reported HCV sales of close to $60 million from the US market in 3Q17, a YoY fall of ~19.5%. AbbVie also reported HCV sales of close to $216 million from international markets in 3Q17, a YoY fall of 29.8% on an operational basis and a fall of 28.7% on a reported basis.
General Electric Company's (GE) segment GE Healthcare will now help to create a digital platform with Roche to advance medicinal treatments particularly for cancer and critical care patients.